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Recently, an association was found between nondiabetic
kidney disease in African Americans and two independent
sequence variants in the APOL1 gene, encoding
apolipoprotein L1. In this study we determined the frequency
of APOL1 risk variants in patients with biopsy-proven HIV-
associated nephropathy (HIVAN) and distinctive pathological
characteristics potentially driven by those risk variants.
Among 76 patients with HIVAN, 60 were successfully
genotyped for APOL1 G1 and G2 polymorphisms. In this
cohort, 37 had two risk alleles, 18 were heterozygous, and 5
had neither risk variant. There were no differences in the
pathological findings of HIVAN and the number of APOL1 risk
alleles. Further, the progression to end-stage kidney disease
or death did not differ by the number of risk alleles. Median
renal survival was 9.3 months in patients with zero or one
risk allele compared to 11.7 months in patients with two
APOL1 risk alleles. Thus, our study suggests that although the
majority of African-American patients with HIVAN have two
APOL1 risk alleles other as yet unknown factors in the host,
including genetic risk variants and environmental or viral
factors, may influence the development of this disorder in
those with zero or one APOL1 risk allele.
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It has long been recognized that individuals with African
ancestry with or without HIV infection have higher
cumulative lifetime risk of end-stage kidney disease (ESKD),
higher frequency of kidney disease, and faster progression to
ESKD.1–3 It is calculated that the cumulative lifetime risks for
ESKD are 7.8, 7.3, 2.5, and 1.8% for a 20-year-old black
woman, black man, white man, and white woman,
respectively.2 Familial clustering of disparate etiologies of
kidney disease (e.g., diabetes-attributed ESKD, hypertension-
attributed ESKD, and HIV-associated nephropathy (HI-
VAN)) also has been observed in African-American families.4
HIVAN is a distinct phenotype induced by HIV-1 infection
and is the most aggressive kidney disease in HIV-1-infected
patients. The strong predilection of the disorder for
individuals of African descent implies the existence of host
genetic variations to explain this racial predilection. A genetic
susceptibility locus has been identified in the transgenic
mouse model of HIVAN.5 These animal studies suggested
that HIVAN in this setting is linked to susceptibility alleles
that along with viral proteins induce latent perturbations in
the podocyte gene expression network.6 In humans, using
genome-wide mapping by admixture linkage disequilibrium,
Kopp et al.7 found several alleles within the MYH9 gene on
chromosome 22 (a gene expressed in glomerular podocytes),
with higher frequency among African Americans with
HIVAN compared with African-American controls. To date,
no causal sequence variation in MYH9 has been identified. It
was also noted that many African Americans with HIV-1
infection and who carry these risk alleles at the MYH9 locus
do not develop HIVAN, suggesting that other susceptibility
factors or ‘multiple hits’ must exist to initiate the disease
process. Recently, a stronger association was demonstrated
between nondiabetic kidney disease in African Americans
and two independent sequence variants in the nearby gene,
APOL1, encoding apolipoprotein L1.8,9 Genovese et al.8
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demonstrated an odds ratio of 10.5 (95% confidence interval
(CI) 6.0–18.4) for idiopathic focal segmental glomerulo-
sclerosis (FSGS) and 7.3 (95% CI 5.6–9.5) for hypertension-
attributed ESKD. Similarly, Kopp et al.10 have shown that the
presence of two APOL1 risk alleles is associated with an odds
ratio of 17 for primary FSGS and 29 for HIVAN, compared
with zero or one APOL1 risk allele. The APOL1 risk variants
appear to confer resistance to some trypanosomal infections,
the cause of African sleeping sickness, which may explain
their high frequency in populations of West African descent.8
The current study was designed to determine the fre-
quency of APOL1 risk variants in patients with biopsy-proven
HIVAN and examine distinctive pathological characteristics
that are potentially driven by those risk variants.
RESULTS
This study included 76 HIV-infected African Americans with
biopsy-proven HIVAN. DNA could not be amplified in 17
patients, leaving 61 patients in the study cohort who were
successfully genotyped for APOL1 using kidney biopsy
tissue. On pathological review, all HIVAN cases were
confirmed as such, except for one case, which was determined
to have non-collapsing FSGS and was excluded from the
present study. The final analysis was limited to 60 cases, of
whom 37 (62%) were homozygous for the G1 and G2 risk
alleles, 18 (30%) were heterozygous, and 5 (8%) had neither
risk variant.
As shown in Table 1, the proportion of patients with a
history of illicit drug use was significantly higher in those
with combined 0/1 APOL1 risk allele compared with those
with two APOL1 risk alleles (78.3 vs. 47.2% respectively,
P¼ 0.03). Even upon the exclusion of those with 0 APOL1
risk allele, the proportion of patients with a history of illicit
drug use was significantly higher in those with one APOL1
risk allele compared with those with two APOL1 risk alleles
(77.8 vs. 47.2%, respectively, P¼ 0.04). There were no
significant differences in age, sex, hepatitis C virus coinfec-
tion, kidney function, proteinuria, exposure to renin–angio-
tensin–aldosterone system blockers at the time of biopsy or
after biopsy, or steroid therapy at the time of biopsy across
the APOL1 risk allele groups (Table 1). Similarly, there were
no differences observed in HIV viral load, CD4þ cell count,
or the proportion of patients on antiretroviral therapy at the
time of biopsy across the APOL1 risk allele groups. None of
the patients had suppressed viral load defined aso50 copies/
ml at the time of biopsy.
Pathological characteristics of patients with two APOL1
risk alleles
Morphological features of HIVAN by the number of APOL1
risk alleles are compared in Table 2. The groups were similar,
although those with 1/0 APOL1 risk allele had a trend toward
more hyalinosis compared with those with two APOL1 risk
alleles (P¼ 0.05). Severity of disease as manifested by the
number of cellular or fibrous crescents, number of collapsed
glomeruli, proportion with severe interstitial inflammation,
and tubular atrophy was not significantly different across the
APOL1 risk allele groups.
Risk of ESKD and mortality associated with APOL1
During 79.4 person-years of follow-up, progression to ESKD
occurred in 31 participants, of whom 22 had two APOL1 risk
Table 1 | Baseline characteristics of the study population
Characteristics
All patients
(N=60)
2 APOL1 risk
alleles (N=37)
1/0 APOL1
risk allele (N=23) P-value
Mean age, years (s.d.) 42.7 (8.1) 41.7 (8.3) 44.3 (7.6) 0.23
Women, n (%) 29 (48) 21 (56.8) 8 (34.8) 0.09
Diabetes, n (%) 6 (10) 2 (5.4) 4 (17.4) 0.13
Hypertension, n (%) 34 (56.7) 22 (59.5) 12 (52.2) 0.58
Hepatitis C, n (%) 32 (53.3) 17 (46.0) 15 (65.2) 0.15
Hepatitis B, n (%) 4 (6.7) 2 (5.4) 2 (8.7) 0.62
Illicit drug use history, n (%) 35 (59.3) 17 (47.2) 18 (78.3) 0.03
[n=59] [n=36] [n=23]
ART use at biopsy, n (%) 13 (24.5) 8 (24.2) 5 (25.0) 1.0
[n=53] [n=33] [n=20]
ACE inhibitor/ARB use at biopsy, n (%) 3 (15.8) 0.0 (0.0) 3 (37.5) 0.06
[n=19] [n=11] [n=8]
ACE inhibitor/ARB use after biopsy, n (%) 18 (37.5) 11 (36.7) 7 (38.9) 1.0
[n=48] [n=30] [n=18]
Glucocorticoid use after biopsy, n (%) 24(46.2) 18 (54.6) 6 (31.6) 0.15
[n=21] [n=12] [n=9]
Mean HIV viral load, 1000 copies/ml (s.d.) at the time of biopsy 194 (218) 206 (225) 173 (211) 0.63
[n=50] [n=32] [n=18]
Mean CD4+ cell count, cells/mm3 (s.d.) 164 (185) 176 (205) 145 (153) 0.56
Mean proteinuria, g/24 h (s.d.) 8.7 (8.8) 8.4 (8.5) 9.2 (9.5) 0.72
Mean serum creatinine, mg/dl (s.d.) 5.4 (3.3) 5.3 (2.7) 5.5 (4.2) 0.79
Mean estimated GFR, ml/min 1.73m2 (s.d.) 20.9 (19.3) 18.3 (14.8) 25.2 (24.8) 0.46
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ART, antiretroviral therapy; GFR, glomerular filtration rate; HIV, human
immunodeficiency virus.
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alleles. Individuals with two APOL1 risk alleles experienced
similar progression to ESKD compared with those with 0/1
risk alleles (Figure 1). In the unadjusted analyses, individuals
with two APOL1 risk alleles had similar risk of ESKD
compared with those with 0/1 risk alleles (Table 3).
Individuals with diabetes at the time of kidney biopsy had
a significantly greater risk of ESKD (hazard ratio
(HR)¼ 3.34, CI 1.11–10.05, Po0.03). In the adjusted
analyses, increasing age was associated with 6% lower risk
of ESKD per year of increase (HR¼ 0.94, CI 0.88–1,
P¼ 0.05). Diabetes remained significantly associated with
ESKD risk (HR¼ 18.96 CI 3.38–106.28, P¼ 0.001; Table 3).
During 238.9 person-years of follow-up, individuals with
two APOL1 risk alleles experienced the same mortality
compared with those with 1/0 risk alleles (Figure 2). No
difference in the combined outcome of ESKD and mortality
was observed across the APOL1 risk allele groups (Supple-
mentary Figure S1 online).
DISCUSSION
The study suggests that although the majority of African-
American patients with HIVAN in our cohort have two
APOL1 risk alleles other unknown genetic risk variants or
host factors must exist to explain the development of HIVAN
in those with 0/1 APOL1 risk allele, and that the absence of
two risk alleles does not exclude the risk for HIVAN in HIV-
infected persons. Compared with those with two risk alleles,
the presence of one or no risk alleles was not correlated with
clinical or histological features in our study. Further, we
found that inheritance of two copies of APOL1 risk variants
conferred no greater risk of disease progression or mortality
than inheritance of 0/1 risk allele.
Genovese et al.8 reported the strongest association signals
with FSGS in African Americans in the APOL1 region rather
than in the neighboring MYH9 region. The APOL1 missense
variants S342G:I384M (G1) and nonsense deletion N388/
Y389 (G2) are more strongly associated with ESKD risk than
the MYH9 risk variants. The APOL1 allele frequency is
estimated to be 430% in African Americans, whereas 8–13%
of African Americans carry two copies of APOL1 risk alleles
G1 or G2.8 Our study highlights the high frequency of
the two APOL1 risk variants (62%) in patients with HIVAN.
Table 2 | Correlation between biopsy findings and APOL1 genotype
Characteristics All patients (N=54) 2 APOL1 risk alleles (N=32) 1/0 APOL1 risk allele (N=22) P-value
Total glomeruli assessed, mean number (s.d.) 18.2 (10.6) 19.1 (10.9) 16.8 (10.2) 0.40
Cellular crescents+, n (%)
0 48 (94.1) 30 (96.7) 18 (90.0) 0.15
1 2 (3.9) 0 (0.0) 2 (10.0)
2 1 (2.0) 1 (3.2) 0 (0.0)
Fibrous crescents+, n (%)
0 47 (92.2) 28 (90.3) 19 (95.0) 0.15
1 3 (5.9) 3 (9.7) 0 (0.0)
2 1 (1.9) 0 (0.0) 1 (5.0)
No. of globally sclerosed gloms+ (s.d.) 6.8 (8.4) 8.4 (9.9) 4.4 (4.8) 0.21
No. of segmentally sclerosed gloms+ (s.d.) 1.8 (1.4) 1.7 (2.3) 2 (2.6) 0.36
No. of gloms w/ collapse+ (s.d.) 2.8 (1.2) 2.9 (1.2) 2.6 (1.2) 0.56
Hyalinosis (%) 27 (50) 12 (37.5) 15 (68.2) 0.05
Severe interstitial inflammation, n (%) 15 (27.8) 11 (34.4) 4 (18.8) 0.13
Severe interstitial fibrosis, n (%) 35 (64.8) 22 (68.8) 13 (59.1) 0.50
Severe tubular atrophy, n (%) 34 (63.0) 22 (68.6) 12 (54.6) 0.40
Tubular cysts, n
0 15 (28.3) 8 (25.0) 7 (33.3) 0.85
1 37 (69.8) 23 (71.9) 14 (66.7)
2 1 (1.9) 1 (3.1) 0 (0.0)
Vascular disease, n (%) 24 (44.4) 18 (56.3) 6 (27.3) 0.15
Data are presented as mean (s.d.) or count (percentage). Only subjects with glomeruliX5 (n=51) were included in analyses and are denoted ‘+’.
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Figure 1 |Kaplan–Meier estimate of renal survival in two
groups of study patients (0/1 APOL1 risk allele and 2 APOL1
alleles). Median renal survival was 9.3 months (interquartile range
(IQR) 3.6, 14.6) in patients with 0/1 APOL1 risk allele compared
with 11.7 months (IQR 3.4, 24.5) in those with two APOL1 risk
alleles, P¼ 0.31 (log-rank test).
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This is compared with 21% in patients with type 2 diabetes
mellitus and ESKD, 11% in nondiabetic controls, and 1.8% in
type 2 diabetes mellitus without kidney disease.11 Despite this
strong association of APOL1 risk variants with HIVAN,
which may also explain the 3- to 4-fold increased risk for
ESKD in African Americans compared with European
Americans in the general population, our study suggests that
homozygosity for the G1 or G2 risk alleles is not necessary for
the development of HIVAN in HIV-infected individuals.
Other chromosome 22 genetic risk variants in addition to
APOL1 risk alleles, the influences of other modifying genes,
or nongenetic factors may explain the appearance of HIVAN
in those lacking two APOL1 risk alleles. Therefore, the search
for other susceptibility variants in patients with HIVAN
remains a critical challenge. Further, it would be premature
to recommend genetic testing to identify those at increased
risk for HIVAN. Furthermore, it is important to note that the
current study only provides an estimate of the sensitivity, not
the specificity, of such a screening test.
Histologically, HIVAN is characterized by prominent
hypertrophic and proliferating glomerular epithelial cells,
leading to the formation of pseudocrescents filling the
Bowman’s space, combined with collapse of the glomerular
capillary tuft and often with microcystic tubular dilatation.12
If left untreated, HIVAN almost invariably progresses to
ESKD within weeks to months.13 In this study, APOL1 risk
alleles did not correlate with any histological features of
HIVAN or influence progression to ESKD or mortality. This
suggests that although APOL1 variants may confer a risk for
HIVAN they do not influence the pathological manifestations
of the disease, and that diverse interaction between genetic
background and HIV can produce an identical clinico-
pathologic syndrome. Recently, our group in collaboration
with others explored the APOL1 risk variants in HIV-infected
individuals with kidney disease other than HIVAN.14
Notably, two APOL1 risk alleles were found in 63% of
individuals with classical FSGS, which is remarkably similar
in frequency to those individuals with HIVAN in this study.
Thus, this may suggest that APOL1 strongly increases
susceptibly to podocyte injury in African Americans with
or without HIV infection. The nature of the resulting
histological injury pattern (glomerulosclerosis or cellular
proliferation) may be influenced by other factors that remain
to be determined. It could be argued, however, that our
patients had quite advanced disease by the time they were
diagnosed, and perhaps it was difficult to observe a difference
in outcomes at this late stage. Substance use in this cohort
involved cocaine, heroin, or both. Cocaine has been
demonstrated to be associated with kidney disease in HIV-
infected individuals.15 Interestingly, the proportion with
illicit drug use was significantly higher among those with 0
or 1 APOL1 risk allele, and indeed it was significantly higher
among those with one vs. two APOL1 risk alleles. These data
would fit with a model of gene–environment interaction,
whereby either two APOL1 risk alleles plus HIV infection or
one APOL1 risk allele plus HIV infection together with illicit
drug use work in synergy to produce HIVAN. Alternatively,
it is possible that our study may have been underpowered to
detect small differences among the groups.
The mechanism by which APOL1 risk variants increase
susceptibility to nondiabetic kidney disease such as FSGS or
HIVAN is undetermined. Glomerular podocytes manifest
high levels of autophagy under basal conditions to maintain
cellular homeostasis.16 APOL1 overexpression induces auto-
phagic cell death in two cancer cell lines;17,18 whether these
Table 3 | Hazard ratios of ESKD associated with APOL1 risk alleles
Univariate Multivariate
Variable
Hazard ratio (95%
confidence interval) P-value
Hazard ratio (95%
confidence interval) P-value
APOL1, 2 vs. 0/1 risk alleles 0.89 (0.43–1.86) 0.76 0.62 (0.27–1.46) 0.28
Age, per increase of year 0.99 (0.94–1.04) 0.71 0.94 (0.88–1.0) 0.05
Female 0.59 (0.33–1.85) 0.59 —
Hepatitis C antibody seropositivity 1.71 (0.80–3.67) 0.17 —
Diabetic 3.34 (1.11–10.05) 0.03 18.96 (3.38–106.28) 0.001
Hypertensive 0.61 (0.30–1.32) 0.21 —
HIV-1 RNA level, per 1 log10 increase 1.00 (0.88–1.15) 0.97 —
CD4+ cell count, per increase of 1 cell/mm3 1.00 (0.99–1.00) 0.28 —
Baseline eGFR, per increase of 1ml/min per 1.73 m2 higher 0.99 (0.96–1.01) 0.21 0.98 (0.96–1.01) 0.18
Proteinuric at biopsy mg/g increase 0.97 (0.91–1.03) 0.36 0.96 (0.89–1.03) 0.21
Abbreviations: eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HIV, human immunodeficiency virus.
Shown are the results for univariable and multivariable models predicting ESKD. In the multivariable model, only the presence of diabetes was associated with an increased
risk for ESKD.
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Figure 2 |Kaplan–Meier estimate of survival in two groups of
study patients (0/1 APOL1 risk allele and 2 APOL1 alleles).
Median survival was 34.2 months (interquartile range (IQR) 16.6,
77.1) in patients with 0/1 APOL1 risk allele compared with 20.1
months (IQR 12.5, 34.3) in those with two APOL1 risk alleles,
P¼ 0.40 (log-rank test).
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findings are relevant for glomerular cells remains to be
determined. On the other hand, inhibition of autophagy
using inhibitors of class III phosphatidylinostol 3-kinase
such as Wortmannin and 3-methyladenine blocks APOL1-
induced autophagic cell death.18 In mice, podocyte-specific
deletion of autophagy-related gene 5 (Atg5) leads to a
glomerulopathy in aging mice, accompanied by an accumu-
lation of oxidized and ubiquitinated proteins, endoplasmic
reticulum stress, and proteinuria. These changes ultimately
result in podocyte loss and late-onset glomerulosclerosis.16
Whether the glomerulopathy that occurs in HIV-1-infected
individuals is driven by alteration in autophagic signaling
pathways as a result of those specific APOL1 risk alleles is
unclear and requires further investigation.
Our study has a number of limitations. Although our
analyses were based on a recessive model for APOL1 where
two risk alleles increase the risk of disease, others have
suggested some increase in risk with a single risk allele.19 Our
study, however, lacked power to distinguish between 0 and 1
risk allele to examine this issue. The biopsies were performed
in the context of clinical care, and therefore the timing of the
biopsies was not standardized. Nevertheless, the biopsies in
both genotype groups were similar in terms of HIV disease
(CD4þ cells counts) and kidney disease (mean serum
creatinine). Many biopsies were performed late in the course
of HIVAN, as evidenced by the mean serum creatinine of
approximately 5 mg/dl, and this may have limited our ability
to discern a difference in progression rate between genotype
groups. The number of cases studied was modest, although
similar in size to other published studies of HIVAN biopsies.
The limited numbers of patients on angiotensin-converting
enzyme inhibitor/angiotensin-receptor blockers use at the
time of biopsy (n¼ 18) did not allow us to study the
potential renal benefit of these agents in this cohort.
In conclusion, our study offers further insights into the
genotype/phenotype correlation in African-American pa-
tients with HIVAN. APOL1 risk variants strongly increase
susceptibility to podocyte injury in African Americans with
HIV infection, similar to African Americans without HIV
infection noted in other studies. Further work is required to
delineate potential interactions between host genetic back-
ground, environmental factors, and viral factors that trigger
disease initiation and progression. As not all patients with
HIV disease and two APOL1 risk alleles develop HIVAN, and
others develop HIVAN with 0 or 1 APOL1 risk allele, it is
clear that HIVAN results from a complex interplay of host
and viral factors.
MATERIALS AND METHODS
Study design and population
Archived percutaneous native kidney biopsies from African-American
HIV-infected adults performed at the Johns Hopkins Hospital
between January 1996 and December 2009 were collected. Only
those with a biopsy report diagnosing HIVAN/collapsing glomerulo-
pathy were included in the study. Biopsies from 78 such patients were
obtained for genotyping (see genotyping details below). DNA could
not be amplified in 17 patients, leaving 61 patients in the study
cohort. This study was approved by the Institutional Review
Boards of the Johns Hopkins University School of Medicine and
the National Institute of Diabetes and Digestive and Kidney
Diseases, NIH.
Histopathologic review of biopsy material
Of the 61 genotyped cases, original slides were only available on 54
cases (the remaining 7 cases, HIVAN diagnosis was based on
pathology reports using the same criteria to define HIVAN) were
available and were reviewed by a pathologist masked to the genotype
(MK). After the review, findings were compared with the pathology
reports (all performed by pathologists other than MK). If the review
findings were different from the original report, a second pathologist
(LR), also masked to the genotype, reviewed the slides and made the
final ruling on the findings.
Genotyping assay for formalin-fixed paraffin-embedded
tissue
Oxidized tissue was removed by cutting five 5-mm sections from the
face of each formalin-fixed paraffin-embedded block, and five 10-
mm sections were cut and placed into 1.5-ml microcentrifuge tubes.
A volume of 175 ml of microwave retrieval solution (0.1% guanidium
thiocyanate and 0.1 mol/l NaOH) was added and heated to 100 1C
over 10 min, followed by heating for an additional 10 min at 100 1C
using the microwave module of a Milestone RH-1 microwave tissue
processor (Hacker Instruments and Industries, Winnsboro, SC).20
Samples were placed into a Thermomixer (Eppendorf, Hauppauge,
NY) for 5 min at 65 1C, and then centrifuged for 5 min at 14,000g at
4 1C. The lysates were transferred to fresh tubes, leaving the paraffin
behind. DNA was isolated using the phenol-based AutoGenprep
245T DNA extraction kit according to the method of the manu-
facturer (Autogen, Holiston, MA). DNA was suspended in 10 mmol/
l Tris, pH 8.0. Yield and purity were determined using the NanDrop
1000 spectrophotometer (NanoDrop Technologies, Thermo Scien-
tific, Wilmington, DE). DNA was stored at 20 1C until subsequent
assay/analyses.
Genotyping APOL1
The APOL1 G1 allele (comprising single-nucleotide polymorphisms
(SNPs) rs73885319 and rs60910145) and the G2 6 bp deletion
(rs717185313) were genotyped by TaqMan assays (ABI, Foster City,
CA). As the HIVAN group comprises cases only, we tested the three
SNPs for conformance to Hardy–Weinberg expectations using the
same TaqMan probes and conditions among an independent set of
383 African-American subjects using a w2 goodness-of-fit test; the
SNPs conformed to Hardy–Weinberg expectations (P40.05) in an
African-American control group (data not shown).
Statistical analyses
Baseline characteristics and renal histopathological findings were
compared according to the number of APOL1 risk alleles using the
Kruskal–Wallis test for continuous variables and w2 test for categorical
variables. Variables with skewed distributions were log10 transformed.
We evaluated the association of APOL1 risk alleles with time to
ESKD using survival analysis methods. Renal survival times were
determined from the time of kidney biopsy to ESKD (defined as an
eGFR below 15 ml/min per 1.73 m2 on initiation of dialysis).
Participants were censored at the last available visit, death, or on
30 June 2011. Kaplan–Meier estimates were calculated, and incident
342 Kidney International (2012) 82, 338–343
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ESKD rates were compared between those with two APOL1 risk
alleles and those with 0 or 1 risk allele. Unadjusted and adjusted Cox
proportional hazards models were constructed to determine the HR
for ESKD and the corresponding 95% CI. Covariates in the final
model were selected based on their clinical and statistical significance
on univariate analyses. A parallel survival analysis was conducted
to study the association of APOL1 risk alleles with time to all-
cause mortality. Survival times were determined from the time of
kidney biopsy to death, and participants were censored at the last
available visit or on 30 June 2011. Statistical analyses were
performed using the Stata/MP 11.2 statistical software (StataCorp,
College Station, TX).
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